Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Benign Prostatic Hyperplasia (BPH): full-pipeline trial registry
3 of 4 indexed Benign Prostatic Hyperplasia (BPH) trials are currently recruiting.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Benign Prostatic Hyperplasia (BPH): 4 US clinical trials tracked, 3 recruiting.
Benign Prostatic Hyperplasia (BPH) is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Siami, Paul F., M.D., running 1 of these trials.
Enrollment posture brief
Registry condition benign-prostatic-hyperplasia-bph
OPEN 3 | RECR 75% | LATE 1 | EARLY 1 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)
Benign Prostatic Hyperplasia (BPH) lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Benign Prostatic Hyperplasia (BPH) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Benign Prostatic Hyperplasia (BPH) is recruiting above its size-band peers.
3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Post-Market Study to Assess iTind Safety in Comparison to UroLift
Olympus Corporation of the Americas
NCT04757116
Effects of TNF Blockade on Human BPH/LUTS
Endeavor Health
NCT06062875
Laser Ablation a Salvage Treatment for Obstructive Benign Prostatic Hyperplasia
The Cleveland Clinic
NCT07016620
Dutasteride With Tolterodine ER or Placebo to Treat Lower Urinary Tract Symptoms (LUTS)
Siami, Paul F., M.D.
NCT00939120
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Benign Prostatic Hyperplasia (BPH) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Benign Prostatic Hyperplasia (BPH) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Benign Prostatic Hyperplasia (BPH) page
4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Benign Prostatic Hyperplasia (BPH) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Siami, Paul F., M.D. sponsors the most Benign Prostatic Hyperplasia (BPH) trials on record, review their full trial history before evaluating a specific study. See Siami, Paul F., M.D.'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Benign Prostatic Hyperplasia (BPH) condition card totals 4 registered trials; most-linked intervention Pre-randomization Dutasteride; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.